EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting the PI3K/AKT/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expression

Ziwei Liang, Yang Ge, Jianjian Li, Yunting Bai, Zeru Xiao, Rui Yan, Guangyu An, Donglei Zhang

Journal of Cancer Research and Clinical Oncology · 2024

DOI: 10.1007/s00432-024-05875-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von Ziwei Liang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Beijing Chao Yang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu Road, Chaoyang Dist., Beijing, 100020, Chin…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Doublecortin-Like Kinases, TOR Serine-Threonine Kinases, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Capital Medical University Undergraduate Science and Technology Innovation Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cholangiocarcinoma (CCA), characterized by high heterogeneity and extreme malignancy, has a poor prognosis. Doublecortin-like kinase 1 (DCLK1) promotes a variety of malignant cancers in their progression. Targeting DCLK1 or its associated regulatory pathways can prevent the generation and deterioration of several malignancies. However, the role of DCLK1 in CCA progression and its molecular mechanisms remain unknown. Therefore, we aimed to investigate whether and how DCLK1 contributes to CCA progression.

Methods

The expression of DCLK1 in CCA patients was detected using Immunohistochemistry (IHC). We established DCLK1 knockout and DCLK1 overexpression cell lines for Colony Formation Assay and Transwell experiments to explore the tumor-promoting role of DCLK1. RT-PCR, Western blot and multiple fluorescent staining were used to assess the association between DCLK1 and epithelial–mesenchymal transition (EMT) markers. RNA sequencing and bioinformatics analysis were performed to identify the underlying mechanisms by which DCLK1 regulates CCA progression and the EMT program.

Results

DCLK1 was overexpressed in CCA tissues and was associated with poor prognosis. DCLK1 overexpression facilitated CCA cell invasion, migration, and proliferation, whereas DCLK1 knockdown reversed the malignant tendencies of CCA cells, which had been confirmed both in vivo and in vitro. Furthermore, we demonstrated that DCLK1 was substantially linked to the advancement of the EMT program, which included the overexpression of mesenchymal markers and the downregulation of epithelial markers. For the underlying mechanism, we proposed that the PI3K/AKT/mTOR pathway is the key process for the role of DCLK1 in tumor progression and the occurrence of the EMT program. When administered with LY294002, an inhibitor of the PI3K/AKT/mTOR pathway, the tumor’s ability to proliferate, migrate, and invade was greatly suppressed, and the EMT process was generally reversed.

Conclusions

DCLK1 facilitates the malignant biological behavior of CCA cells through the PI3K/AKT/mTOR pathway. In individuals with cholangiocarcinoma who express DCLK1 at high levels, inhibitors of the PI3K/AKT/mTOR signaling pathway may be an effective therapeutic approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaDoublecortin-Like KinasesTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktProtein Serine-Threonine KinasesBile Duct NeoplasmsIntracellular Signaling Peptides and ProteinsPhosphatidylinositol 3-KinasesSignal TransductionHumansMaleAnimalsFemaleMiceEpithelial-Mesenchymal TransitionCell Line, TumorPrognosisMiddle AgedCell ProliferationMice, NudeXenograft Model Antitumor AssaysGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

CholangiocarcinomaDCLK1Epithelial-mesenchymal transformationPI3K/AKT/mTOR pathway

Substanzen

Doublecortin-Like KinasesTOR Serine-Threonine KinasesDCLK1 protein, humanProto-Oncogene Proteins c-aktProtein Serine-Threonine KinasesMTOR protein, humanIntracellular Signaling Peptides and ProteinsPhosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Department of Oncology, Beijing Chao Yang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu Road, Chaoyang Dist., Beijing, 100020, China.
  • Department of Basic Medical Sciences, School of Medicine, Tsinghua-Peking Center for Life Sciences, Institute for Immunology, Tsinghua University, Beijing, 100084, China.
  • Department of Oncology, Beijing Chao Yang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu Road, Chaoyang Dist., Beijing, 100020, China. agybjcy@163.com.
  • Department of Gastroenterology, Beijing Chao Yang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu Road, Chaoyang Dist., Beijing, 100020, China. zdlzdl52973@sina.com.

Förderung

  • Capital Medical University Undergraduate Science and Technology Innovation Fund

Zitieren

APA

Liang, Z., Ge, Y., Li, J., Bai, Y., Xiao, Z., Yan, R., An, G., & Zhang, D. (2024). Targeting the PI3K/AKT/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expression. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05875-3

Vancouver

Liang Z, Ge Y, Li J, Bai Y, Xiao Z, Yan R, et al. Targeting the PI3K/AKT/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expression. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05875-3

BibTeX
@article{Liang2024,
  author = {Liang, Ziwei and Ge, Yang and Li, Jianjian and Bai, Yunting and Xiao, Zeru and Yan, Rui and An, Guangyu and Zhang, Donglei},
  title = {Targeting the PI3K/AKT/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expression},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  doi = {10.1007/s00432-024-05875-3}
}
Kostenlos starten →